Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesDose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer
Journal of Thoracic Oncology, 07/01/09
Kepka L et al. - In a trial to determine the efficacy of accelerated hypofractionated 3-dimensional conformal radiotherapy (3D-CRT) with dose-per-fraction escalation for treatment of stage III non-small cell lung cancer (NSCLC), it appears that although dose escalation with accelerated hypofractionated 3D-CRT was limited, results and toxicity profiles obtained using this technique are promising.
Methods- 173 pts with stage III NSCLC were treated using accelerated 3D-CRT and the simultaneous boost technique.
- The total dose of 56.7 Gy (including 39.9 Gy to elective area) was delivered over 4 wks in fractions of 2.7 Gy (1.9 Gy to elective area).
- Dose-per-fraction escalation study commenced after the outcomes of 70 pts had been evaluated.
- Dose per fraction was increased from 2.7 through 2.8 Gy (level 1 escalation) to 2.9 Gy (level 2 escalation); total dose increased, respectively, from 56.7 Gy through 58.8 Gy to 60.9 Gy.
- Dose to the elective area and overall treatment time remained unchanged.
- Fit pts received 2 to 3 courses of chemotherapy before radiotherapy.
- 2- and 3-yr overall survival rates were 32% and 19%, respectively.
- Of the pts, 7% had grade III acute esophageal toxicity and 6% had grade III or greater late pulmonary toxicity.
- 2 of 9 pts who received level 2 escalation (60.9 Gy) died of pulmonary toxicity.
- The study was terminated at a dose of 58.8 Gy; this schema was adopted as institutional policy for treatment of stage III NSCLC.
Today in Diagnostics/Radiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Sponsor
Article Search
Sponsor
Sponsor